



2012

Antibiotic Prevention of Acute Exacerbations of COPD

Richard P. Wenzel

Virginia Commonwealth University, rwenzel@mcvh-vcu.edu

Alpha A. Fowler

Virginia Commonwealth University, afowler@mcvh-vcu.edu

Michael B. Edmond

Virginia Commonwealth University, medmond@mcvh-vcu.edu

Follow this and additional works at: http://scholarscompass.vcu.edu/vcuhealth_pubs



Part of the [Medicine and Health Sciences Commons](#)

From The New England Journal of Medicine, Wenzel, R. P., Fowler, A. A., Edmond, M. B., Antibiotic Prevention of Acute Exacerbations of COPD, Vol. 367, Page 340, Copyright © 2012 Massachusetts Medical Society.

Downloaded from

http://scholarscompass.vcu.edu/vcuhealth_pubs/11

This Article is brought to you for free and open access by the VCU Health at VCU Scholars Compass. It has been accepted for inclusion in VCU Health Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

CLINICAL THERAPEUTICS

Antibiotic Prevention of Acute Exacerbations of COPD

Richard P. Wenzel, M.D., Alpha A. Fowler III, M.D.,
and Michael B. Edmond, M.D., M.P.H., M.P.A.

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors' clinical recommendations.

From the Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond. Address reprint requests to Dr. Wenzel at 1 Capital Sq., 830 E. Main St., Richmond, VA 23219, or at rwenzel@mcvh-vcu.edu.

N Engl J Med 2012;367:340-7.

DOI: 10.1056/NEJMct1115170

Copyright © 2012 Massachusetts Medical Society.

A 55-year-old man presents with a history of recurrent exacerbations of chronic obstructive pulmonary disease (COPD) during the past year. These episodes were characterized by increased shortness of breath, cough, and sputum production. The diagnosis of COPD was made 2 years previously. Pulmonary-function testing then revealed a forced expiratory volume in 1 second (FEV₁) of 50% of the predicted value after bronchodilator inhalation, with a ratio of FEV₁ to forced vital capacity (FVC) of 60%. The patient had a 30-pack-year smoking history but stopped smoking after chronic lung disease was diagnosed. On the current visit, he is afebrile and has a resting pulse of 84 beats per minute. A careful review confirms that he is knowledgeable about proper inhaler use and that he is compliant with his medications, which include maintenance therapy with salmeterol and fluticasone as well as albuterol plus ipratropium as needed for intermittent therapy for increased dyspnea. His physician recommends the use of azithromycin at a dose of 250 mg daily to reduce the frequency of acute exacerbations.

THE CLINICAL PROBLEM

An estimated 24 million persons in the United States have COPD on the basis of lung-function testing.¹ Globally, COPD is the fourth leading cause of death,² and in the United States it is the third most common cause of death and chronic complications.³

The average person with COPD has one to two acute exacerbations each year, with wide variation from patient to patient.⁴ In 2000 in the United States, 726,000 patients were hospitalized with acute exacerbations of COPD.¹ During an acute exacerbation, antibiotics are generally administered for 5 to 10 days,⁵ creating a national burden of 120 million to 480 million antibiotic-days annually. The median hospital stay per exacerbation has been estimated at 9 days.⁶ In a 2007 Canadian study, the median cost of a hospital stay after an acute exacerbation of COPD was \$9,557 (Canadian dollars).⁷

Acute exacerbations of COPD requiring hospitalization are associated with a 30-day rate of death from any cause of 4 to 30%.⁶ A study in Sweden showed an all-cause mortality of 26% at 30 days and of 69% at 3 years.⁸ Acute exacerbations also accelerate the progressive decline in lung function associated with COPD. Overall, the FEV₁ falls by approximately 33 ml per year in patients with COPD.⁴ Each acute exacerbation increases the rate of decline by an additional 2 ml per year⁴ and by up to 7 ml per year in smokers.⁶

 PATHOPHYSIOLOGY AND EFFECT OF THERAPY

COPD is characterized by chronic airway inflammation resulting in increased mucus production and airway ciliary malfunction. The inflammatory process leads to destruction of respiratory bronchioles, parenchymal loss, and thickening of the vascular wall.^{9,10} With progressive limitation of airflow and decrements of both oxygen and carbon dioxide exchange, elevated pulmonary-artery pressures and eventually right ventricular hypertrophy and right heart failure (cor pulmonale) develop in some patients.¹¹ Expiratory airflow obstruction is a prominent clinical feature and the key measure of disease progression.

Exacerbations of COPD have been shown to coincide with acute respiratory viral infections, including those with picornaviruses, influenza virus, and respiratory syncytial virus.¹² At the same time, the sputum of patients with COPD is colonized with bacteria, often with newly acquired strains of known pathogens such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*.¹³ Lines of evidence linking bacteria to acute exacerbations include the finding of new bacterial strains in 33% of patients seen in clinics for exacerbations,¹³ a correlation between bacterial colonization of lower airways and elevated levels of inflammatory mediators (e.g., tumor necrosis factor α , interleukin-6, and interleukin-8),¹⁴⁻¹⁶ a correlation between substantial bacterial infection of small airways and acute exacerbations,¹⁷⁻²⁰ and improved outcomes after antibiotic treatment.²¹

Members of the macrolide class of antibiotics — including erythromycin, clarithromycin, and azithromycin — inhibit bacterial RNA-directed protein assembly by binding to the 50S subunit of bacterial ribosomes.²² In addition to their antimicrobial efficacy, macrolides have been shown to have antiinflammatory and immune-modulating effects.²³ It has been shown that these drugs decrease the production of cytokines in the lungs²⁴ (Fig. 1). In most clinical trials, 90% or more of patients with acute exacerbations of COPD who were treated with macrolides had increased rates of early clinical response.²⁵

 CLINICAL EVIDENCE

A recent large clinical trial by Albert et al.²⁶ involving 1142 volunteers examined the hypothesis

that daily administration of 250 mg of azithromycin for 1 year would reduce the frequency of acute exacerbations of COPD. Among the participants, 570 received azithromycin and 572 received placebo. Among patients in the azithromycin group, the median time to the first acute exacerbation was increased by 92 days (from 174 days in the placebo group to 266 days in the azithromycin group). The frequency of exacerbations was 1.48 per year in the azithromycin group versus 1.83 in the placebo group (hazard ratio in the azithromycin group, 0.73; 95% confidence interval [CI], 0.63 to 0.84; $P < 0.001$). Quality of life, as measured by the St. George's Respiratory Questionnaire, improved to a greater degree in the azithromycin group than in the placebo group. There was no significant difference in overall mortality between the groups. Patients with risk factors for adverse effects of azithromycin were excluded from the trial. Potential participants were not enrolled if they had known hearing impairment (as documented on audiometric testing) or a corrected QT (QTc) interval of more than 450 msec or if they were using other medications (except amiodarone) that could prolong the QTc interval. Patients with a resting pulse rate of more than 100 beats per minute were also excluded.

In another long-term, placebo-controlled clinical trial examining macrolide antibiotics in the prevention of acute exacerbations of COPD involving 109 patients, erythromycin was the active drug, given at a dose of 250 mg twice daily for 1 year.²⁷ The primary outcome was the number of moderate or severe exacerbations (as treated with systemic glucocorticoids, antibiotics, or hospitalization). The rate ratio for exacerbations in the erythromycin group was 0.65 (95% CI, 0.49 to 0.86; $P = 0.003$).

 CLINICAL USE

All patients with the diagnosis of COPD should be treated according to the recommendations in current guidelines. Recent updates to the American College of Physicians guidelines²⁸ and the Global Initiative for Chronic Obstructive Lung Disease (known as GOLD) report²⁹ make broadly similar recommendations for COPD management. These include smoking cessation, enrollment in a pulmonary rehabilitation program, and the use of evidence-based medications, including long-




Figure 1. Activation of the Immune Response by Bacteria or Viruses within the Airway of Patients with COPD.

Pathogens in the luminal airway induce the secretion of chemokines (tumor necrosis factor α , interleukin-6, and interleukin-8) and leukotrienes by both macrophages and airway epithelium. This process triggers vascular adhesion and migration of neutrophils into the wall of the airway and into airway lumens. Serine proteases and other mediators that are secreted by migrating neutrophils both inflame the airways and destroy bronchial epithelium, leading to clinical exacerbation. Azithromycin inhibits bacteria and down-regulates certain key parts of the immune response, thus providing a protective activity when used prophylactically.

acting inhaled beta-agonists, long-acting inhaled anticholinergic agents, and inhaled glucocorticoids. It is also important to assess and emphasize proper inhaler use and compliance with all aspects of therapy.

A patient who continues to have frequent acute exacerbations despite guidelines-based treatment is a potential candidate for prophylactic use of azithromycin (Table 1). In our view, a patient should have had at least two episodes of acute exacerbation in the previous year to be considered for such therapy, both to provide a baseline against which to assess clinical response and to limit overuse of azithromycin in the wider population of patients with COPD. Patients with any of the exclusion criteria that were used in the trial by Albert et al.²⁶ should not take azithromycin. The resting pulse rate should be less than 100 beats per minute, and the patient should undergo electrocardiography to rule out a QTc of more than 450 msec and formal audiography to exclude any hearing deficit. In addition, the patient should not be taking any drug that is known to increase the QTc interval. Furthermore, since azithromycin is an inhibitor of the cytochrome P-450 enzyme CYP3A4, it should not be used if the patient is taking any drug that is metabolized by that enzyme.

The dose of azithromycin that was used in the clinical trial was 250 mg per day. In earlier pharmacokinetics studies of azithromycin, Foulds et al.³⁰ found that after the administration of 250 mg of azithromycin, the usual serum peak level was 0.4 μ g per milliliter. However, with repeated daily administration, lung-tissue levels were usually 75 times as high, and tissue levels persisted even after serum levels declined. Furthermore, in a murine model of lung infection, Retsema et al. found that azithromycin was bactericidal and that the effect correlated with lung-tissue levels of the drug.³¹ Tissue levels of azithromycin are sufficient for a bactericidal effect after administration three times a week or a larger weekly dose alone. In addition, macrolide prophylaxis has been used successfully in other conditions in regimens ranging from once daily to once weekly to three times weekly (see below). Thus, we do not think that daily administration is necessary, and even though there are no specific data to support this approach, we favor a regimen consisting of 250 mg administered on Monday, Wednesday, and Friday.

Dose adjustment is not needed for renal dys-

Table 1. Proposed Criteria for Selecting Patients with COPD for Long-Term Azithromycin Prophylaxis.

History of COPD with ≥ 2 acute exacerbations in the previous year
Compliance with current drug regimen and proper use of inhaler
Pulse <100 beats per minute
Corrected QT interval of <450 msec on electrocardiography
Aminotransferase levels <3 times the upper limit of normal range
No use of drugs known to cause QT prolongation
No decrement in hearing on formal audiography
No allergy to macrolides
Sputum culture negative for mycobacteria
No high baseline risk of cardiovascular disease

function. However, because macrolides are metabolized in the liver, we suggest not using azithromycin if the patient has moderate or severe liver disease, as indicated by serum aminotransferase levels of more than three times the upper limit of the normal range. This suggestion is not based on published data but is recommended as a precaution.

In adherence to the protocol of the trial by Albert et al.,²⁶ we suggest follow-up evaluations every 3 months, at which time all the initial screening, including audiography and electrocardiography, should be repeated. The physician should ask the patient about hearing problems, disequilibrium, and tinnitus, which might be signs of ototoxicity. In addition, since any antibiotic can select for *Clostridium difficile*, the patient should be asked about diarrhea and other gastrointestinal symptoms.

The cost of generic azithromycin is \$99 per 30 doses (www.drugstore.com). Thus, the annual cost of prophylaxis would be \$1,188 with daily azithromycin use or \$515 with use three times weekly. If approximately three patients need to be treated to prevent one annual exacerbation (as suggested by the results of the large clinical trial), the annual cost to prevent an exacerbation would be \$3,564 (for daily administration) or \$1,545 (for administration three times a week).

ADVERSE EFFECTS

There are three major categories of adverse effects that may be anticipated with yearlong use of azithromycin. These include ototoxicity, cardiac toxicity, and drug–drug interactions.

Hearing loss, disequilibrium, and tinnitus are potential adverse effects of macrolides.³²⁻³⁴ In the trial by Albert et al.,²⁶ there was a 5% differential in hearing loss between the antibiotic-treatment group (25%) and the placebo group (20%). This 5% absolute difference is the best estimate of the hearing loss directly attributable to azithromycin with long-term use. Our review of the literature identified 25 cases of azithromycin-induced ototoxicity. Some of the patients in these studies were also taking drugs metabolized by cytochrome P-450, and in some patients the hearing loss was not reversible during the follow-up period.³⁵⁻⁴⁰

Macrolide antibiotics prolong the QTc interval by blocking a cardiac potassium channel called the human ether-a-go-go-related gene (HERG) channel.⁴¹ A prolonged QTc interval is associated with an increased risk of torsades de pointes, potentially resulting in ventricular fibrillation and sudden death. In a recent large retrospective cohort study, short-term use of azithromycin (5 days) was associated with an estimated 47 additional deaths from cardiovascular causes per 1 million antibiotic courses, as compared with amoxicillin.⁴² Since torsades de pointes is an unusual event, screening patients for a QTc interval of more than 450 msec and excluding them from azithromycin prophylaxis may help minimize the risk (Table 1). Nevertheless, we suggest avoiding the use of azithromycin in patients with a high risk of baseline cardiovascular disease. Such patients include those with congestive heart failure, cerebrovascular disease, and peripheral vascular disease.⁴²

Macrolides also inhibit the CYP3A4 isoenzyme, thus increasing serum levels of other drugs metabolized by this enzyme (Table 1). Azithromycin is a weaker inhibitor than erythromycin or clarithromycin in vitro,⁴³ but caution is still justified on the basis of individual variability in CYP3A4 metabolic activity. Examples of drugs with which potentially important interactions may occur include the statins, resulting in an increased risk of rhabdomyolysis⁴⁴; warfarin, resulting in an increase in the international normalized ratio⁴⁴; and amiodarone, resulting in an increased risk of QTc prolongation and ventricular arrhythmias.⁴⁵

AREAS OF UNCERTAINTY

The development of antibiotic resistance with prolonged azithromycin prophylaxis is an issue of ma-

major concern but one with uncertain clinical implications. In the trial by Albert et al.,²⁶ nasopharyngeal swabs were obtained for assessment of bacterial colonization and antibiotic resistance at the time of enrollment and every 3 months thereafter. The rates of first-time colonization were lower in the azithromycin group than in the placebo group, but the new colonizing organisms were much more likely to be resistant to macrolide antibiotics (81%, vs. 41% in the placebo group). The trial was not large enough and did not have a sufficient duration to permit an assessment of the clinical consequences of this resistance pattern.

Long-term macrolide prophylaxis has been used in a number of other disorders. These conditions include diffuse panbronchiolitis (a chronic inflammatory disease of the bronchioles seen primarily in Japan, China, and Korea),⁴⁶⁻⁴⁸ cystic fibrosis,⁴⁹⁻⁵³ and bronchiectasis.^{54,55} It has also been used in the prevention of *Mycobacterium avium* complex infection in patients with the acquired immunodeficiency syndrome and a CD4+ count below 50 cells per cubic millimeter.⁵⁶ In at least some of these disorders (especially cystic fibrosis), macrolide prophylaxis has been associated with significant increases in the rate of antibiotic resistance but without apparent adverse consequences for the treatment of subsequent acute exacerbations.

A related concern is that of the wider spread of macrolide-resistant organisms from patients being treated prophylactically to the general population. In one study, in patients with COPD who received a macrolide antibiotic within 6 months after a follow-up culture, the rate of isolation of *S. pneumoniae* resistant to a macrolide in sputum (54%) was nearly four times that in unexposed controls (14%).⁵⁷ In theory, close contacts and family members of patients with antibiotic-resistant strains could acquire the organism.

The wider spread of resistance could also be a problem for the management of other organisms for which macrolide antibiotics are used. Azithromycin is commonly administered to treat legionella and mycoplasma infections, but fluoroquinolones are well established as alternative agents for these pathogens. Of greater concern is the importance of macrolide therapy in the management of infections with nontuberculous mycobacteria, which can infect patients with COPD. Some experts are promoting the idea of screening patients with COPD for colonization with nontuberculous mycobacteria and withholding macrolide prophylaxis.

laxis in those with positive sputum cultures (Fennelly K, Griffith D: personal communication). We concur with this recommendation (Table 1).

The two above-mentioned clinical trials evaluated the effects of a single year of macrolide prophylaxis, leaving unresolved the question of whether to continue long-term prophylaxis in patients with this chronic disease. The experience with long-term macrolide prophylaxis in patients with other diseases offers some reassurance that azithromycin can be continued after the first year. We would suggest discontinuing the drug if important adverse effects surface or if the number of exacerbations does not decrease during the first year of treatment. This may be especially likely among patients with advanced COPD, whose disease course is typically characterized by an increased number of exacerbations.⁵⁸

Additional concerns relate to the risk of known long-term adverse events. Will hearing loss be additive, and will the rate of this adverse effect increase? Will QTc-related arrhythmias develop even if patients are carefully selected? Continued screening will be necessary during ongoing prophylaxis. Population-based studies should be carried out to examine success rates, adverse drug events, and the effect of antibiotic resistance after long-term prophylaxis with azithromycin.

It is unknown whether other antibiotics could be as effective as, or more effective than, azithromycin in patients with COPD. Clinicians treating pulmonary patients with long-term prophylaxis have primarily used macrolides. Of the available macrolides, azithromycin is the most studied and the one with the fewest adverse effects. Few other antibiotics have recently been studied for this purpose. In one trial, patients with stable COPD were randomly assigned to receive either moxifloxacin at a dose of 400 mg daily or placebo for 5 days every 8 weeks for 48 weeks. The mean exacerbation rate was 0.88 with moxifloxacin and 0.94 with placebo, a difference that was not significant.⁵⁹ In our view, quinolones should not be preferred over macrolides for COPD prophylaxis, because they are so important for treating community-acquired pneumonia.

GUIDELINES

The use of azithromycin for the prevention of COPD exacerbations has not been endorsed by current expert guidelines. The GOLD report²⁹ states that “a recent trial of daily azithromycin showed efficacy on exacerbation end points; however, treatment is not recommended because of an unfavorable balance between benefits and side effects.” A recent update to the American College of Physicians guidelines²⁸ does not mention the use of prophylactic antibiotics.

RECOMMENDATIONS

The patient described in the vignette is representative of those with COPD with at least two exacerbations in the previous year. He is knowledgeable about proper inhaler use and is compliant with his medications. Before prolonged use of azithromycin is recommended, he should have a hearing test, electrocardiography to assess his QTc interval, and a sputum culture for mycobacterial species. If he has no evidence of hearing impairment and a normal QTc interval, and if the sputum culture is negative, it is reasonable to prescribe azithromycin at a dose of 250 mg to be administered on Mondays, Wednesdays, and Fridays.

The patient should be followed at 3-month intervals and should be routinely asked about the onset of any hearing loss, tinnitus, or disequilibrium. A careful review of all medications should be carried out to identify any potential drug–drug interactions. At each 3-month visit, he should undergo formal audiography and electrocardiography to rule out new hearing issues or an increased QTc interval, respectively. At the end of 1 year, he should have a careful reevaluation for adverse effects as well as for evidence of a reduction in the frequency of COPD exacerbations. If there is clear evidence of benefit, it is reasonable to consider continuing azithromycin prophylaxis with appropriate monitoring.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES

- Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance — United States, 1971–2000. *MMWR Surveill Summ* 2002;51(SS-6):1-16.
- Mathers CD, Boerma T, Ma Fat D. Global and regional causes of death. *Br Med Bull* 2009;92:7-32.
- Murphy SL, Xu J, Kochanek KD. Deaths: preliminary data for 2010. *Natl Vital Stat Rep* 2012;60(4):1-68.
- Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011;365:1184-92.
- Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C. Exacerbations of chronic obstructive pulmonary disease:

- when are antibiotics indicated? A systematic review. *Respir Res* 2007;8:30. [Erratum, *Respir Rev* 2008;9:81.]
6. Donaldson GC, Wedzicha JA. COPD exacerbations. 1. Epidemiology. *Thorax* 2006;61:164-8.
 7. Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. *Respir Med* 2007;102:413-21.
 8. Berkus J, Nolin T, Mårdh C, Karlström G, Walther SM. Characteristics and long-term outcome of acute exacerbations in chronic obstructive pulmonary disease: an analysis of cases in the Swedish Intensive Care Registry during 2002-2006. *Acta Anaesthesiol Scand* 2008;52:759-65.
 9. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV₁. *Am J Respir Crit Care Med* 1997;155:852-7.
 10. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. *N Engl J Med* 2011;365:1567-75.
 11. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1994;150:833-52.
 12. Rohde G, Wiethage A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization: a case-control study. *Thorax* 2003;58:37-42.
 13. Sethi S, Murphy TF. Infection in the pathologies and course of chronic obstructive pulmonary disease. *N Engl J Med* 2008;359:2355-65.
 14. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. *J Clin Invest* 2008;118:3546-56.
 15. Soler N, Ewig S, Torres A, Filelia X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. *Eur Respir J* 1999;14:1015-22.
 16. Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic *Haemophilus influenzae* airway infections: comparison with noninfected patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;162:947-52.
 17. Fagon JY, Chastre J, Trouillet J, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis: use of the protected specimen brush technique in 54 mechanically ventilated patients. *Am Rev Respir Dis* 1990;142:1004-8.
 18. Monsó E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. *Am J Respir Crit Care Med* 1995;152:1316-20.
 19. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. *Am J Respir Crit Care Med* 1998;157:1498-505.
 20. Pela R, Marchesani F, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. *Monaldi Arch Chest Dis* 1998;53:262-7.
 21. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196-204.
 22. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F. Antibacterial macrolides: a drug class with a complex pharmacological profile. *Pharmacol Res* 2004;50:211-22.
 23. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2008;3:331-50.
 24. Kano H, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. *Clin Microbiol Rev* 2010;23:590-615.
 25. Milstone AP. Use of azithromycin in the treatment of acute exacerbations of COPD. *Int J Chron Obstruct Pulmon Dis* 2008;3:515-20.
 26. Albert RK, Connert J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. *N Engl J Med* 2011;365:689-98. [Erratum, *N Engl J Med* 2012;366:1356.]
 27. Seemungal TAR, Wilkinson TMA, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. *Am J Respir Crit Care Med* 2008;178:1139-47.
 28. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Ann Intern Med* 2011;155:179-91.
 29. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2011 (<http://www.goldcopd.org/>).
 30. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. *J Antimicrob Chemother* 1990;25:Suppl A:73-82.
 31. Retsema JA, Girard AE, Girard D, Milisen WB. Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo. *J Antimicrob Chemother* 1990;25:Suppl A:83-9.
 32. Williams JD. Evaluation of the safety of macrolides. *Int J Antimicrob Agents* 2001;18:Suppl 1:S77-S81.
 33. Coulston J, Balaratnam N. Irreversible sensorineural hearing loss due to clarithromycin. *Postgrad Med J* 2005;81:58-9.
 34. Rubinstein E. Comparative safety of the different macrolides. *Int J Antimicrob Agents* 2001;18:Suppl 1:S71-S76.
 35. Tseng AL, Dolovich L, Salit IE. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. *Clin Infect Dis* 1997;24:76-7.
 36. Bizjak ED, Haug MT III, Schilz RJ, Sarodia BD, Dressing JM. Intravenous azithromycin-induced ototoxicity. *Pharmacotherapy* 1999;19:245-8.
 37. Mamikoglu B, Mamikoglu O. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity: a case report. *Ann Otol Rhinol Laryngol* 2001;110:102.
 38. Röss BD, Gross EM. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity: a case report. *Ann Otol Rhinol Laryngol* 2000;109:435-7.
 39. Wallace MR, Miller LK, Nguyen MT, Shields AR. Ototoxicity with azithromycin. *Lancet* 1994;343:241.
 40. Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ Jr. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. *Clin Infect Dis* 1997;24:958-64.
 41. Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. *J Pharmacol Exp Ther* 2002;302:320-7.
 42. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. *N Engl J Med* 2012;366:1881-90.
 43. von Rosenstiel NA, Adam D. Macrolide antibacterials: drug interactions of clinical significance. *Drug Saf* 1995;13:105-22.
 44. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. *Br J Clin Pharmacol* 2000;50:285-95.
 45. Samarendra P, Kumari S, Evans SJ, Sacchi TJ, Navarro V. QT prolongation associated with azithromycin/amiodarone combination. *Pacing Clin Electrophysiol* 2001;24:1572-4.
 46. Keicho N, Kudoh S. Diffuse panbronchiolitis: role of macrolides in therapy. *Am J Respir Med* 2002;119:31.
 47. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchi-

- olitis treated with low-dose erythromycin. *Am J Respir Crit Care Med* 1998; 157:1829-32.
48. Park S-J, Lee Y-C, Rhee Y-K, Lee H-B. The effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis. *Biochem Biophys Res Commun* 2004;324:114-7.
49. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: a randomized controlled trial. *JAMA* 2003; 290:1749-56.
50. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. *Thorax* 2002;57:212-6.
51. Hansen CR, Pressler T, Hoiby N, Johansen HK. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in *Staphylococcus aureus* in Danish CF patients. *J Cyst Fibros* 2009;8:58-62.
52. Phaff SJ, Tiddens HAWM, Verbrugh HA, Ott A. Macrolide resistance of *Staphylococcus aureus* and *Haemophilus* species associated with long-term azithromycin use in cystic fibrosis. *J Antimicrob Chemother* 2006;57:741-6.
53. Tramper-Stranders GA, Wolfs TFW, Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. *Pediatr Infect Dis J* 2007;26:8-12.
54. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. *Thorax* 2004;59:540-1.
55. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. *Respir Med* 2008;102:1494-6.
56. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007;175:367-416. [Erratum, *Am J Respir Crit Care Med* 2007;175:744-5.]
57. Desai H, Richter S, Doern G, et al. Antibiotic resistance in sputum isolates of *Streptococcus pneumoniae* in chronic obstructive pulmonary disease is related to antibiotic exposure. *COPD* 2010;7:337-44.
58. Benfield T, Lange P, Vestbo J. COPD stage and risk of hospitalization for infectious disease. *Chest* 2008;134:46-53.
59. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Respir Res* 2010;11:10. [Erratum, *Respir Res* 2010;11:88.]

Copyright © 2012 Massachusetts Medical Society.

SPECIALTIES AND TOPICS AT NEJM.ORG

Specialty pages at the *Journal's* website (NEJM.org) feature articles in cardiology, endocrinology, genetics, infectious disease, nephrology, pediatrics, and many other medical specialties. These pages, along with collections of articles on clinical and nonclinical topics, offer links to interactive and multimedia content and feature recently published articles as well as material from the NEJM archive (1812–1989).